Jump to content

Lorazepam

From Wikipedia, the free encyclopedia
Not to be confused withLoprazolam,Lormetazepam,orLoratadine.

Lorazepam
Clinical data
Trade namesAtivan, Tavor, Temesta, others[1]
Other nameso-Chloroxazepam
AHFS/DrugsMonograph
MedlinePlusa682053
License data
Pregnancy
category
  • AU:C
Dependence
liability		High[2]
Addiction
liability		Moderate[3][4]
Routes of
administration		orally,intramuscular,intravenous,transdermal
Drug classBenzodiazepine
ATC code
Legal status
Legal status
Pharmacokineticdata
Bioavailability85% when taken by mouth
MetabolismLiverglucuronidation
Onset of action1–5 min (IV), 15–30 min (IM)[7]
Eliminationhalf-life10–20 hours[8][9][10]
Duration of action12–24 hours (IV, IM)[7]
ExcretionKidney
Identifiers
  • (RS)-7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.011.534Edit this at Wikidata
Chemical and physical data
FormulaC15H10Cl2N2O2
Molar mass321.16g·mol−1
3D model (JSmol)
  • O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
  • InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)checkY
  • Key:DIWRORZWFLOCLC-UHFFFAOYSA-NcheckY
☒NcheckY(what is this?)(verify)
a box of Lorazepam Orion (Lorazepam) tablets

Lorazepam,sold under the brand nameAtivanamong others, is abenzodiazepinemedication.[7]It is used to treatanxiety(includinganxiety disorders),trouble sleeping,severe agitation,activeseizuresincludingstatus epilepticus,alcohol withdrawal,andchemotherapy-induced nausea and vomiting.[7]It is also used during surgery tointerfere with memory formationand tosedatethose who are beingmechanically ventilated.[7][11]It is also used, along with other treatments, foracute coronary syndromedue tococaineuse.[7]It can be givenorally(by mouth),transdermal(on the skin via a topical gel or patch),intravenously(IV) (injection into a vein), orintramuscularly(injection into a muscle.)[7]When given by injection, onset of effects is between one and thirty minutes and effects last for up to a day.[7]

Common side effects include weakness, sleepiness,low blood pressure,and a decreased effort to breathe.[7]When given intravenously, the person should be closely monitored.[7]Among those who aredepressed,there may be an increased risk ofsuicide.[7][12]With long-term use,larger doses may be required for the same effect.[7]Physical dependenceandpsychological dependencemay also occur.[7]If stopped suddenly after long-term use,benzodiazepine withdrawal syndromemay occur.[7]Older people more often develop adverse effects.[13]In this age group, lorazepam is associated with falls andhip fractures.[14]Due to these concerns, lorazepam use is generally only recommended for up to two to four weeks.[15]

Lorazepam was initially patented in 1963 and went on sale in the United States in 1977.[16][17]It is on theWorld Health Organization's List of Essential Medicines.[18]It is available as ageneric medication.[7]In 2021, it was the 78th most commonly prescribed medication in the United States, with more than 8million prescriptions.[19][20]

Medical uses[edit]

Anxiety[edit]

Lorazepam is used in the short-term management of severe anxiety. In the US, the FDA advises against use of benzodiazepines such as lorazepam for longer than four weeks.[15][21]It is fast acting, and useful in treating fast onset panic anxiety.[22]

Lorazepam can effectively reduce agitation and induce sleep, and the duration of effects from a single dose makes it an appropriate choice for the short-term treatment ofinsomnia,especially in the presence of severe anxiety or night terrors. It has a fairly short duration of action.[23]

Withdrawal symptoms, includingrebound insomnia and rebound anxiety,may occur after seven days' use of lorazepam.[24]

Seizures[edit]

Lorazepam 3mg scored tablets in a blister pack.

Intravenousdiazepamor lorazepam are first-line treatments for convulsivestatus epilepticus.[25]Lorazepam is more effective than diazepam and intravenousphenytoinin the treatment of status epilepticus and has a lower risk of continuing seizures that might require additional medication.[26]However,phenobarbitalhas a superior success rate compared to lorazepam and other drugs, at least in the elderly.[27][28]

Lorazepam'santiconvulsantproperties andpharmacokinetic profilemake intravenous use reliable for terminatingacute seizures,but induce prolonged sedation. Oral benzodiazepines, including lorazepam, are occasionally used as long-termprophylactictreatment of resistantabsence seizures;because of gradualtoleranceto their anti-seizure effects, benzodiazepines such as lorazepam are not considered first-line therapies. Additionally, common seizure characteristics (hypersalivation, jaw-clenching, involuntary swallowing, etc.) pose some difficulties with regard to oral administration.[29][30]

Lorazepam's anticonvulsant and CNS depressant properties are useful for the treatment and prevention ofalcohol withdrawal syndrome.In this setting, impaired liver function is not a hazard with lorazepam, since lorazepam does not require oxidation, in the liver or otherwise, for its metabolism. Lorazepam is noted as being the most tolerable benzodiazepine in those with advanced-stage liver disease.[31][32][33]

Sedation[edit]

Lorazepam is sometimes used for individuals receivingmechanical ventilation.However, in critically ill people,propofolhas been found to be superior to lorazepam both in effectiveness and overall cost; as a result, the use of propofol for this indication is now encouraged, whereas the use of lorazepam is discouraged.[34]

Its relative effectiveness in preventing new memory formation,[35]along with its ability to reduce agitation and anxiety, makes lorazepam useful aspremedication.It is given before a general anesthetic to reduce the amount of anesthetic required, or before unpleasant awake procedures, such as in dentistry or endoscopies, to reduce anxiety, to increase compliance, and to induce amnesia for the procedure. Lorazepam by mouth is given 90 to 120 minutes before procedures, andintravenouslorazepam as late as 10 minutes before procedures.[36][37][38]Lorazepam is sometimes used as an alternative tomidazolaminpalliative sedation.[39]Inintensive care unitslorazepam is sometimes used to produceanxiolysis,hypnosis,andamnesia.[40]

Agitation[edit]

Lorazepam is sometimes used as an alternative tohaloperidolwhen there is the need for rapidsedationof violent or agitated individuals,[41][42]but haloperidol plus promethazine is preferred due to better effectiveness and due to lorazepam's adverse effects on respiratory function.[43]However, adverse effects such as behavioral disinhibition may make benzodiazepines inappropriate for some people who are acutely psychotic.[44]Acutedeliriumis sometimes treated with lorazepam, but as it can causeparadoxical effects,it is preferably given together with haloperidol.[45]Lorazepam is absorbed relatively slowly if given intramuscularly, a common route in restraint situations.

Other[edit]

Catatoniawith inability to speak is responsive to lorazepam. Symptoms may recur and treatment for some days may be necessary. Catatonia due to abrupt or overly rapid withdrawal from benzodiazepines, as part of thebenzodiazepine withdrawal syndrome,should also respond to lorazepam treatment.[46]As lorazepam can have paradoxical effects,haloperidolis sometimes given at the same time.[45][47]

It is sometimes used inchemotherapyin addition tomedications used to treat nausea and vomiting,i.e. nausea and vomiting caused or worsened by psychological sensitization to the thought of being sick.[48]

Adverse effects[edit]

Many beneficial effects of lorazepam (e.g., sedative, muscle relaxant, anti-anxiety, and amnesic effects) may become adverse effects when unwanted.[35]Adverse effects can include sedation andlow blood pressure;the effects of lorazepam are increased in combination with otherCNS depressantdrugs.[25][41]Other adverse effects include confusion,ataxia,inhibiting the formation of new memories, pupil constriction and hangover effects. Withlong-term benzodiazepine useit is unclear whether cognitive impairments fully return to normal after stopping lorazepam use; cognitive deficits persist for at least six months after withdrawal, but longer than six months may be required for recovery of cognitive function. Lorazepam appears to have more profound adverse effects on memory than other benzodiazepines; it impairs bothexplicitandimplicit memory.[49][50]In the elderly, falls may occur as a result of benzodiazepines. Adverse effects are more common in the elderly, and they appear at lower doses than in younger people. Benzodiazepines can cause or worsendepression.Paradoxical effectscan also occur, such as worsening of seizures, or paradoxical excitement; paradoxical excitement is more likely to occur in the elderly, children, those with a history of alcohol abuse, and in people with a history of aggression or anger problems.[13]Lorazepam's effects are dose-dependent, meaning the higher the dose, the stronger the effects (and side effects) will be. Using the smallest dose needed to achieve desired effects lessens the risk of adverse effects. Sedative drugs and sleeping pills, including lorazepam, have been associated with an increased risk of death.[51]

Sedation is the side effect people taking lorazepam most frequently report. In a group of around 3,500 people treated for anxiety, the most common side effects complained of from lorazepam were sedation (15.9%), dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Side effects such as sedation and unsteadiness increased with age.[52]Cognitive impairment, behavioral disinhibition and respiratory depression as well ashypotensionmay also occur.[40][44]

  • Paradoxical effects: In some cases, paradoxical effects can occur with benzodiazepines, such as increased hostility, aggression, angry outbursts, and psychomotor agitation. These effects are seen more commonly with lorazepam than with other benzodiazepines.[53]Paradoxical effects are more likely to occur with higher doses, in people with pre-existingpersonality disordersand those with a psychiatric illness. Frustrating stimuli may trigger such reactions, though the drug may have been prescribed to help the person cope with such stress and frustration in the first place. As paradoxical effects appear to be dose-related, they usually subside on dose reduction or on complete withdrawal of lorazepam.[54][55][56][57][58][59]
  • Suicidality: Benzodiazepines are associated with increased risk of suicide, possibly due todisinhibition.[12]Higher dosages appear to confer greater risk.
  • Amnesic effects: Among benzodiazepines, lorazepam has relatively strongamnesiceffects,[35][60]but people soon develop tolerance to this with regular use. To avoid amnesia (or excess sedation) being a problem, the initial total daily lorazepam dose should not exceed 2 mg. This also applies to use for night sedation. Five participants in a sleep study were prescribed lorazepam 4 mg at night, and the next evening, three subjects unexpectedly volunteered memory gaps for parts of that day, an effect that subsided completely after two to three days' use.[61]Amnesic effects cannot be estimated from the degree of sedation present, since the two effects are unrelated.
  • High-dose or prolonged parenterally-administered lorazepam with its associatedsolventcan cause propylene glycol intoxication and poisoning.[40][62]

In September 2020, the U.S.Food and Drug Administration(FDA) required theboxed warningbe updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.[63]

Contraindications[edit]

Lorazepam should be avoided in people with:

  • Allergyorhypersensitivity– Past hypersensitivity or allergy to lorazepam, to any benzodiazepine, or to any of the ingredients in lorazepam tablets or injections
  • Respiratory failure– Benzodiazepines, including lorazepam, may depress central nervous system respiratory drive and are contraindicated in severe respiratory failure. An example would be the inappropriate use to relieve anxiety associated withacute severe asthma.The anxiolytic effects may also be detrimental to a person's willingness and ability to fight for breath. However, ifmechanical ventilationbecomes necessary, lorazepam may be used to facilitate deep sedation.
  • Acute intoxication– Lorazepam may interact synergistically with the effects ofalcohol,narcotics, or other psychoactive substances. It should, therefore, not be administered to a drunk or intoxicated person.
  • Ataxia– This is a neurological clinical sign, consisting of unsteady and clumsy motion of the limbs and torso, due to the failure of gross muscle movement coordination, most evident on standing and walking. It is the classic way in which acute alcohol intoxication may affect a person. Benzodiazepines should not be administered to people already-ataxic.
  • Acute narrow-angleglaucoma– Lorazepam has pupil-dilating effects, which may further interfere with the drainage ofaqueous humorfrom the anterior chamber of the eye, thus worsening narrow-angleglaucoma.
  • Sleep apnea– Sleep apnea may be worsened by lorazepam's central nervous system depressant effects. It may further reduce the person's ability to protect his or her airway during sleep.[64]
  • Myasthenia gravis– This condition is characterized by muscle weakness, so a muscle relaxant such as lorazepam may exacerbate symptoms.
  • Pregnancyandbreastfeeding– Lorazepam belongs to theFood and Drug Administration(FDA) pregnancy category D, which means it is likely to cause harm to the developing baby if taken during the first trimester of pregnancy. The evidence is inconclusive whether lorazepam if taken early in pregnancy results in reduced intelligence, neurodevelopmental problems, physical malformations in cardiac or facial structure, or other malformations in some newborns. Lorazepam given to pregnant women antenatally may causefloppy infant syndrome[65]in the neonate, or respiratory depression necessitating ventilation. Regular lorazepam use during late pregnancy (thethird trimester), carries a definite risk ofbenzodiazepine withdrawal syndromein the neonate. Neonatal benzodiazepine withdrawal may includehypotonia,reluctance to suck,apneicspells,cyanosis,and impairedmetabolicresponses to cold stress. Symptoms of floppy infant syndrome and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.[66]Lorazepam may also inhibit fetal liver bilirubin glucuronidation, leading to neonatal jaundice. Lorazepam is present in breast milk, so caution must be exercised about breastfeeding.

Specific groups[edit]

  • Children and the elderly – The safety and effectiveness of lorazepam is not well determined in children under 18 years of age, but it is used to treat acute seizures. Dose requirements have to be individualized, especially in people who are elderly and debilitated in whom the risk of oversedation is greater. Long-term therapy may lead to cognitive deficits, especially in the elderly, which may only be partially reversible. The elderly metabolize benzodiazepines more slowly than younger people and are more sensitive to the adverse effects of benzodiazepines compared to younger individuals even at similar plasma levels. Additionally, the elderly tend to take more drugs which may interact or enhance the effects of benzodiazepines. Benzodiazepines, including lorazepam, have been found to increase the risk of falls and fractures in the elderly. As a result, dosage recommendations for the elderly are about half of those used in younger individuals and used for no longer than two weeks.[13][67]Lorazepam may also be slower to clear in the elderly, leading potentially to accumulation and enhanced effects.[68]Lorazepam, similar to other benzodiazepines andnonbenzodiazepines,causes impairments in body balance and standing steadiness in individuals who wake up at night or the next morning. Falls and hip fractures are frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete, tolerance develops to these impairments.[14]
  • Liverorkidney failure– Lorazepam may be safer than most benzodiazepines in people withimpaired liver function.Likeoxazepam,it does not require liver oxidation, but only liver glucuronidation into lorazepam-glucuronide. Therefore, impaired liver function is unlikely to result in lorazepam accumulation to an extent causing adverse reactions.[31]Similarlykidneydisease has minimal effects on lorazepam levels.[69]
  • Drug and alcohol dependence– The risk of abuse of lorazepam is increased in dependent people.[67]
  • Comorbidpsychiatric disordersalso increase the risk of dependence and paradoxical adverse effects.[67]

Tolerance and dependence[edit]

Dependence typified by a withdrawal syndrome occurs in about one-third of individuals who are treated for longer than four weeks with a benzodiazepine. Higher doses and longer periods of use increase the risk of developing abenzodiazepine dependence.Potent benzodiazepines with a relatively short half life, such as lorazepam,alprazolam,andtriazolam,have the highest risk of causing a dependence.[13]

If regular treatment is continued for longer than four to six months, dose increases may be necessary to maintain effects, but treatment-resistant symptoms may in fact bebenzodiazepine withdrawal symptoms.[70]Due to the development of tolerance to theanticonvulsanteffects, benzodiazepines are generally not recommended for long-term use for the management of epilepsy. Increasing the dose may overcome tolerance, but tolerance may then develop to the higher dose and adverse effects may persist and worsen. The mechanism of tolerance to benzodiazepines is complex and involvesGABAAreceptordownregulation, alterations to subunit configuration of GABAAreceptors,uncouplingandinternalisationof the benzodiazepine binding site from the GABAAreceptor complex as well as changes ingene expression.[13]

The likelihood of dependence is relatively high with lorazepam compared to other benzodiazepines. Lorazepam's relatively short serum half-life, its confinement mainly to blood, and its inactive metabolite can result in interdose withdrawal phenomena and next-dose cravings, that may reinforce psychological dependence. Because of its high potency, the smallest lorazepam tablet strength of 0.5 mg is also a significant dose. To minimise the risk of physical/psychological dependence, lorazepam is best used only short-term, at the smallest effective dose. If any benzodiazepine has been used long-term, the recommendation is a gradual dose taper over a period of weeks, months or longer, according to dose and duration of use, the degree of dependence and the individual.

Coming off long-term lorazepam use may be more realistically achieved by a gradual switch to an equivalent dose ofdiazepamand a period of stabilization on this, and only then initiating dose reductions. The advantage of switching to diazepam is that dose reductions are felt less acutely, because of the longer half-lives (20–200 hours) of diazepam and its active metabolites.[71]

Withdrawal[edit]

On abrupt or overly rapid discontinuation of lorazepam, anxiety, and signs of physical withdrawal have been observed, similar to those seen on withdrawal from alcohol and barbiturates. Lorazepam, as with otherbenzodiazepinedrugs, can causephysical dependence,addiction,andbenzodiazepine withdrawal syndrome.The higher the dose and the longer the drug is taken, the greater the risk of experiencing unpleasant withdrawal symptoms. Withdrawal symptoms can, however, occur from standard dosages and also after short-term use. Benzodiazepine treatment should be discontinued as soon as possible via a slow and gradual dose reduction regimen.[72]Rebound effectsoften resemble the condition being treated, but typically at a more intense level and may be difficult to diagnose. Withdrawal symptoms can range from mild anxiety and insomnia to more severe symptoms such asseizuresandpsychosis.The risk and severity of withdrawal are increased with long-term use, use of high doses, abrupt or over-rapid reduction, among other factors. Short-acting benzodiazepines such as lorazepam are more likely to cause a more severe withdrawal syndrome compared to longer-acting benzodiazepines.[13]

Withdrawal symptoms can occur after taking therapeutic doses of lorazepam for as little as one week.[citation needed]Withdrawal symptoms include headaches, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating,dysphoria,dizziness,derealization,depersonalization, numbness/tingling of extremities, hypersensitivity to light, sound, and smell, perceptual distortions, nausea, vomiting, diarrhea, appetite loss, hallucinations, delirium, seizures, tremor, stomach cramps,myalgia,agitation, palpitations,tachycardia,panic attacks, short-term memory loss, and hyperthermia. It takes about 18–36 hours for the benzodiazepine to be removed from the body.[73]The ease of physical dependence to lorazepam, (Ativan brand was particularly cited), and its withdrawal were brought to the attention of the British public during the early 1980s in Esther Rantzen's BBC TV seriesThat's Life!,in a feature on the drug over a number of episodes.

Interactions[edit]

Lorazepam is not usually fatal in overdose, but may cause respiratory depression if taken in overdose with alcohol. The combination also causes greater enhancement of thedisinhibitoryandamnesiceffects of both drugs, with potentially embarrassing or criminal consequences. Some experts advise that people should be warned against drinking alcohol while on lorazepam treatment,[35][74]but such clear warnings are not universal.[75]

Greater adverse effects may also occur when lorazepam is used with other drugs, such asopioidsor otherhypnotics.[69]Lorazepam may also interact withrifabutin.[76]Valproateinhibits the metabolism of lorazepam, whereascarbamazepine,lamotrigine,phenobarbital,phenytoin,andrifampinincrease its rate of metabolism. Some antidepressants, antiepileptic drugs such as phenobarbital, phenytoin and carbamazepine, sedative antihistamines, opiates, antipsychotics and alcohol, when taken with lorazepam may result in enhanced sedative effects.[13]

Overdose[edit]

See also:Benzodiazepine overdose

In cases of a suspected lorazepam overdose, it is important to establish whether the person is a regular user of lorazepam or other benzodiazepines since regular use causes tolerance to develop. Also, one must ascertain whether other substances were also ingested.

Signs of overdose range through mental confusion,dysarthria,paradoxical reactions,drowsiness,hypotonia,ataxia,hypotension,hypnotic state,coma,cardiovascular depression,respiratory depression,anddeath.However, fatal overdoses on benzodiazepines alone are rare and less common than withbarbiturates.[77]Such a difference is largely due to benzodiazepine activity as a neuroreceptormodulator,and not as an activator per se. Lorazepam and similar medications do however act in synergy with alcohol, which increases the risk of overdose.

Early management of people under alert includesemetics,gastric lavage,andactivated charcoal.Otherwise, management is by observation, including of vital signs, support and, only if necessary, considering the hazards of doing so, givingintravenousflumazenil.

People are ideally nursed in a kind, frustration-free environment, since, when given or taken in high doses, benzodiazepines are more likely to cause paradoxical reactions. If shown sympathy, even quite crudely feigned, people may respond solicitously, but they may respond with disproportionate aggression to frustrating cues.[78]Opportunisticcounselinghas limited value here, as the person is unlikely to recall this later, owing to drug-induced anterograde amnesia.

Detection in body fluids[edit]

Lorazepam may be quantitated in blood or plasma to confirm poisoning in hospitalized people, provide evidence of an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma concentrations are usually in a range of 10–300 μg/L in persons either receiving the drug therapeutically or in those arrested for impaired driving. Approximately 300–1000 μg/L is found in people after acute overdosage.[79]Lorazepam may not be detected by commonly usedurine drug screeningsfor benzodiazepines. This is due to the fact that the majority of these screening tests are only able to detect benzodiazepines that undergooxazepamglucuronidemetabolism.[80][81][82]

Pharmacology[edit]

Lorazepam hasanxiolytic,sedative,hypnotic,amnesic,anticonvulsant,andmuscle relaxantproperties.[83]It is a high-potency and anintermediate-acting[clarification needed]benzodiazepine, and its uniqueness,[84][85]advantages, and disadvantages are largely explained by its pharmacokinetic properties (poor water and lipid solubility, high protein binding and anoxidative metabolism to a pharmacologically inactive glucuronide form) and by its high relative potency (lorazepam 1 mg is equal in effect todiazepam10 mg).[86][87]Thebiological half-lifeof lorazepam is 10–20 hours.[88]

Pharmacokinetics[edit]

Lorazepam is highly protein bound and is extensively metabolized into pharmacologically inactive metabolites.[13]Due to its poor lipid solubility, lorazepam is absorbed relatively slowly by mouth and is unsuitable for rectal administration. However, its poor lipid solubility and high degree of protein binding (85–90%[89]) mean its volume of distribution is mainly thevascularcompartment, causing relatively prolonged peak effects. This contrasts with the highly lipid-solublediazepam,which, although rapidly absorbed orally or rectally, soon redistributes from the serum to other parts of the body, in particular, body fat. This explains why one lorazepam dose, despite its shorter serum half-life, has more prolonged peak effects than an equivalent diazepam dose.[90]Lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepamglucuronidewhich is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals. The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months. On regular administration, diazepam will accumulate, since it has a longer half-life and active metabolites, these metabolites also have long half-lives.

Clinical example:Diazepam has long been a drug of choice forstatus epilepticus;its high lipid solubility means it gets absorbed with equal speed whether given orally, or rectally (nonintravenous routes are convenient outside of hospital settings), but diazepam's high lipid solubility also means it does not remain in the vascular space, but soon redistributes into other body tissues. So, it may be necessary to repeat diazepam doses to maintain peak anticonvulsant effects, resulting in excess body accumulation. Lorazepam is a different case; its low lipid solubility makes it relatively slowly absorbed by any route other than intravenously, but once injected, it will not get significantly redistributed beyond the vascular space. Therefore, lorazepam's anticonvulsant effects are more durable, thus reducing the need for repeated doses. If a person is known to usually stop convulsing after only one or two diazepam doses, it may be preferable because sedative after effects will be less than if a single dose of lorazepam is given (diazepam anticonvulsant/sedative effects wear off after 15–30 minutes, but lorazepam effects last 12–24 hours).[91]The prolonged sedation from lorazepam may, however, be an acceptable trade-off for its reliable duration of effects, particularly if the person needs to be transferred to another facility. Although lorazepam is not necessarily better than diazepam at initially terminating seizures,[92]lorazepam is, nevertheless, replacing diazepam as the intravenous agent of choice in status epilepticus.[93][94]

Lorazepam serum levels are proportional to the dose administered. Giving 2 mg oral lorazepam will result in a peak total serum level of around 20 ng/mL around two hours later,[89][95]half of which is lorazepam, half its inactive metabolite, lorazepam-glucuronide.[96]A similar lorazepam dose given intravenously will result in an earlier and higher peak serum level, with a higher relative proportion of unmetabolised (active) lorazepam.[97]On regular administration, maximum serum levels are attained after three days. Longer-term use, up to six months, does not result in further accumulation.[89]On discontinuation, lorazepam serum levels become negligible after three days and undetectable after about a week. Lorazepam is metabolized in the liver by conjugation into inactive lorazepam-glucuronide. This metabolism does not involve liver oxidation, so is relatively unaffected by reduced liver function. Lorazepam-glucuronide is more water-soluble than its precursor, so gets more widely distributed in the body, leading to a longer half-life than lorazepam. Lorazepam-glucuronide is eventually excreted by the kidneys,[89]and, because of its tissue accumulation, it remains detectable, particularly in the urine, for substantially longer than lorazepam.

Pharmacodynamics[edit]

Relative to other benzodiazepines, lorazepam is thought to have high affinity forGABA receptors,[98]which may also explain its marked amnesic effects.[35]Its main pharmacological effects are the enhancement of the effects of the neurotransmitterGABAat the GABAAreceptor.[13]Benzodiazepines, such as lorazepam, enhance the effects of GABA at the GABAAreceptor via increasing the frequency of opening of the chloride ion channel on the GABAAreceptors; which results in the therapeutic actions of benzodiazepines. They, however, do not on their own activate the GABAAreceptors, but require theneurotransmitterGABA to be present. Thus, the effect of benzodiazepines is to enhance the effects of the neurotransmitter GABA.[13][69]

The magnitude and duration of lorazepam effects are dose-related, meaning larger doses have stronger and longer-lasting effects, because the brain has spare benzodiazepine drug receptor capacity, with single, clinical doses leading only to an occupancy of some 3% of the available receptors.[99]

The anticonvulsant properties of lorazepam and other benzodiazepines may be, in part or entirely, due to binding to voltage-dependentsodium channelsrather than benzodiazepine receptors. Sustained repetitive firing seems to get limited, by the benzodiazepine effect of slowing recovery of sodium channelsfrom inactivation to deactivationin mouse spinal cord cell cultures, hence prolonging therefractory period.[100]

Physical properties and formulations[edit]

0.5 mg tablets of the Ativan brand of lorazepam

Pure lorazepam is an almost white powder that is nearly insoluble in water and oil. In medicinal form, it is mainly available as tablets and a solution for injection, but, in some locations, it is also available as a skin patch, an oral solution, and asublingualtablet.

Lorazepam tablets and syrups are administered orally. Lorazepam tablets of the Ativan brand also containlactose,microcrystalline cellulose,polacrilin,magnesium stearate,and coloring agents (indigo carminein blue tablets andtartrazinein yellow tablets). Lorazepam for injection formulated withpolyethylene glycol400 inpropylene glycolwith 2.0%benzyl alcoholas preservative.

Lorazepam injectable solution is administered either by deepintramuscular injectionor byintravenousinjection. The injectable solution comes in 1 mLampoulescontaining 2 or 4 mg of lorazepam. The solvents used arepolyethylene glycol400 andpropylene glycol.As a preservative, the injectable solution containsbenzyl alcohol.[101]Toxicity from propylene glycol has been reported in the case of a person receiving a continuous lorazepam infusion.[102]Intravenous injections should be given slowly and they should be closely monitored for side effects, such as respiratory depression, hypotension, or loss of airway control.

Peak effects roughly coincide with peak serum levels,[95]which occur 10 minutes after intravenous injection, up to 60 minutes after intramuscular injection, and 90 to 120 minutes after oral administration,[89][95]but initial effects will be noted before this. A clinically relevant lorazepam dose will normally be effective for six to 12 hours, making it unsuitable for regular once-daily administration, so it is usually prescribed as two to four daily doses when taken regularly, but this may be extended to five or six, especially in the case of elderly people who could not handle large doses at once.

Topical formulationsof lorazepam, while sometimes used as treatment for nausea especially in people inhospice,has been advised against by theAmerican Academy of Hospice and Palliative Medicinefor this purpose as it has not been proven effective.[103]

History[edit]

1987 advertisement. "In a world where certainties are few...no wonder Ativan is prescribed by so many caring clinicians."

Historically, lorazepam is one of the "classical" benzodiazepines. Others includediazepam,clonazepam,oxazepam,nitrazepam,flurazepam,bromazepam,andclorazepate.[104]Lorazepam was first introduced byWyeth Pharmaceuticalsin 1977 under the brand names Ativan and Temesta.[105]The drug was developed by D.J. Richards, president of research.Wyeth's originalpatenton lorazepam is expired in the United States.

Society and culture[edit]

Recreational use[edit]

See also:Benzodiazepine misuse

Lorazepam is also used for other purposes, such asrecreationaluse, wherein the drug is taken to achieve a high, or when the drug is continued long-term against medical advice.[106]

A 2006 large-scale, nationwide, US government study of pharmaceutical-relatedemergency departmentvisits bySAMHSAfound sedative-hypnotics are the pharmaceuticals most frequently used outside of their prescribed medical purpose in the United States, with 35% of drug-related emergency department visits involving sedative-hypnotics. In this category, benzodiazepines are most commonly used. Males and females use benzodiazepines for nonmedical purposes equally. Of drugs used in attemptedsuicide,benzodiazepines are the most commonly used pharmaceutical drugs, with 26% of attempted suicides involving them. Lorazepam was the third-most-common benzodiazepine used outside of prescription in these ER visit statistics.[107]

Legal status[edit]

Lorazepam is a Schedule IV drug under theControlled Substances Actin the U.S. and internationally under the United NationsConvention on Psychotropic Substances.[108]It is a Schedule IV drug under theControlled Drugs and Substances Actin Canada. In the United Kingdom, it is a Class C, Schedule 4 Controlled Drug under the Misuse of Drugs Regulations 2001.[109]

Pricing[edit]

In 2000, the US drug companyMylanagreed to pay $147 million to settle accusations by theFTCthat they had raised the price of generic lorazepam by 2600% and genericclorazepateby 3200% in 1998 after having obtained exclusive licensing agreements for certain ingredients.[110]

References[edit]

  1. ^"Lorazepam".The Drug Gene Interaction Database.Archivedfrom the original on 5 August 2016.Retrieved18 May2016.
  2. ^Edmunds M, Mayhew M (2013).Pharmacology for the Primary Care Provider(4th ed.). Mosby. p. 545.ISBN978-0-323-08790-2.Archivedfrom the original on 14 January 2023.Retrieved13 July2020.
  3. ^Clinical Addiction Psychiatry.Cambridge University Press. 2010. p. 156.ISBN978-1-139-49169-3.Archivedfrom the original on 8 September 2017.
  4. ^Ries RK (2009).Principles of addiction medicine(4 ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 106.ISBN978-0-7817-7477-2.Archivedfrom the original on 8 September 2017.
  5. ^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)".nctr-crs.fda.gov.FDA.Retrieved22 October2023.
  6. ^Anvisa(31 March 2023)."RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial"[Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União(published 4 April 2023).Archivedfrom the original on 3 August 2023.Retrieved16 August2023.
  7. ^abcdefghijklmno"Lorazepam".drugs.American Society of Health-System Pharmacists. 29 June 2016.Archivedfrom the original on 5 June 2016.Retrieved15 July2016.
  8. ^Greenblatt DJ, Shader RI, Franke K, Maclaughlin DS, Harmatz JS, Allen MD, Werner A, Woo E (1991). "Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans".Journal of Pharmaceutical Sciences.68(1): 57–63.doi:10.1002/jps.2600680119.PMID31453.
  9. ^Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW, Shader RI (2000). "Kinetics and dynamics of lorazepam during and after continuous intravenous infusion".Critical Care Medicine.28(8): 2750–2757.doi:10.1097/00003246-200008000-00011.PMID10966246.S2CID42138460.
  10. ^Papini O, da Cunha SP, da Silva Mathes Ado C, Bertucci C, Moisés EC, de Barros Duarte L, de Carvalho Cavalli R, Lanchote VL (2006). "Kinetic disposition of lorazepam with a focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples".Journal of Pharmaceutical and Biomedical Analysis.40(2): 397–403.doi:10.1016/j.jpba.2005.07.021.PMID16143486.
  11. ^"Lorazepam: MedlinePlus Drug Information".medlineplus.gov.1 October 2010.Archivedfrom the original on 19 August 2016.Retrieved16 July2016.
  12. ^abDodds TJ (March 2017)."Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature".The Primary Care Companion for CNS Disorders.19(2).doi:10.4088/PCC.16r02037.PMID28257172.
  13. ^abcdefghijRiss J, Cloyd J, Gates J, Collins S (2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics".Acta Neurologica Scandinavica.118(2): 69–86.doi:10.1111/j.1600-0404.2008.01004.x.PMID18384456.S2CID24453988.
  14. ^abMets MA, Volkerts ER, Olivier B, Verster JC (2010). "Effect of hypnotic drugs on body balance and standing steadiness".Sleep Medicine Reviews.14(4): 259–267.doi:10.1016/j.smrv.2009.10.008.PMID20171127.
  15. ^ab"Ativan (lorazepam) Tablets Rx only"(PDF).Food and Drug Administration.March 2007.Archived(PDF)from the original on 17 September 2011.In general, benzodiazepines should be prescribed for short periods only (e.g. 2–4 weeks). Extension of the treatment period should not take place without reevaluation of the need for continued therapy. Continuous long-term use of product is not recommended.
  16. ^Shorter E (2005)."B".A Historical Dictionary of Psychiatry.Oxford University Press.ISBN978-0-19-029201-0.Archivedfrom the original on 28 March 2017.
  17. ^US patent 3296249,Stanley C. Bell, "5-monocyclic aryl-1, 3-dihydro-2h-1, 4-benzodiazepin-2-ones", published 1967-01-03, issued 1967-01-03, assigned to American Home Products
  18. ^World Health Organization(2019).World Health Organization model list of essential medicines: 21st list 2019.Geneva: World Health Organization.hdl:10665/325771.WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  19. ^"The Top 300 of 2021".ClinCalc.Archivedfrom the original on 15 January 2024.Retrieved14 January2024.
  20. ^"Lorazepam - Drug Usage Statistics".ClinCalc.Retrieved14 January2024.
  21. ^Rabin RC (25 August 2009)."Disparities: Study Finds Risk in Off-Label Prescribing".The New York Times.p. D6.Archivedfrom the original on 19 February 2017.
  22. ^Lader M (1984). "Short-term versus long-term benzodiazepine therapy".Current Medical Research and Opinion.8(Suppl 4): 120–126.doi:10.1185/03007998409109550.PMID6144459.
  23. ^Aschenbrenner DS, Venable SJ (2009).Drug Therapy in Nursing(3rd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p.273.ISBN978-0-7817-6587-9.OCLC173659630.Archivedfrom the original on 19 April 2016.
  24. ^Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK (1982). "Lorazepam-efficacy, side effects, and rebound phenomena".Clinical Pharmacology and Therapeutics.31(2): 175–179.doi:10.1038/clpt.1982.27.PMID6120058.S2CID464310.
  25. ^abWalker M (2005)."Status epilepticus: an evidence based guide".BMJ.331(7518): 673–677.doi:10.1136/bmj.331.7518.673.PMC1226249.PMID16179702.
  26. ^Prasad M, Krishnan PR, Sequeira R, Al-Roomi K (September 2014)."Anticonvulsant therapy for status epilepticus".The Cochrane Database of Systematic Reviews.2014(9): CD003723.doi:10.1002/14651858.CD003723.pub3.PMC7154380.PMID25207925.
  27. ^Treiman DM, Walker MC (2006). "Treatment of seizure emergencies: convulsive and non-convulsive status epilepticus".Epilepsy Research.68(Suppl 1): S77–S82.doi:10.1016/j.eplepsyres.2005.07.020.PMID16384688.S2CID22205104.
  28. ^Treiman DM (2007)."Treatment of convulsive status epilepticus".The Neurobiology of Epilepsy and Aging.International Review of Neurobiology. Vol. 81. pp.273–285.doi:10.1016/S0074-7742(06)81018-4.ISBN978-0-12-374018-2.PMID17433931.S2CID24523838.
  29. ^Isojärvi JI, Tokola RA (December 1998). "Benzodiazepines in the treatment of epilepsy in people with intellectual disability".Journal of Intellectual Disability Research.42(1): 80–92.PMID10030438.
  30. ^Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. (September 2022)."Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability".CNS Drugs.36(9): 951–975.doi:10.1007/s40263-022-00940-2.PMC9477921.PMID35971024.
  31. ^abPeppers MP (1996)."Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease".Pharmacotherapy.16(1): 49–57.doi:10.1002/j.1875-9114.1996.tb02915.x.PMID8700792.S2CID1389910.
  32. ^Bråthen G, Ben-Menachem E, Brodtkorb E, Galvin R, Garcia-Monco JC, Halasz P, Hillbom M, Leone MA, Young AB (2005)."EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force".European Journal of Neurology.12(8): 575–581.doi:10.1111/j.1468-1331.2005.01247.x.PMID16053464.S2CID25904252.
  33. ^"Lorazepam".LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012.PMID31643878.
  34. ^Cox CE, Reed SD, Govert JA, Rodgers JE, Campbell-Bright S, Kress JP, Carson SS (2008)."An Economic Evaluation of Propofol and Lorazepam for Critically Ill Patients Undergoing Mechanical Ventilation".Critical Care Medicine.36(3): 706–714.doi:10.1097/CCM.0B013E3181544248.PMC2763279.PMID18176312.
  35. ^abcdeHindmarch I (30 January 1997)."Benzodiazepines and their effects".benzo.org.uk.Retrieved13 May2007.
  36. ^Maltais F, Laberge F, Laviolette M (1996)."A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy"(PDF).Chest.109(5): 1195–1198.doi:10.1378/chest.109.5.1195.PMID8625666.Archived fromthe original(PDF)on 7 April 2008.
  37. ^Heisterkamp DV, Cohen PJ (1975)."The effect of intravenous premedication with lorazepam (Ativan), pentobarbital or diazepam on recall".British Journal of Anaesthesiology.47(1): 79–81.doi:10.1093/bja/47.1.79.PMID238548.
  38. ^Tsui BC, Wagner A, Finucane B (2004). "Regional anaesthesia in the elderly: a clinical guide".Drugs Aging.21(14): 895–910.doi:10.2165/00002512-200421140-00001.PMID15554749.S2CID68771929.
  39. ^Verhagen EH, Hesselmann GM, Besse TC, de Graeff A (2005). "(title in Dutch)" [Palliative sedation].Nederlands Tijdschrift voor Geneeskunde(in Dutch).149(9): 458–461.PMID15771339.
  40. ^abcArcangeli A, Antonelli M, Mignani V, Sandroni C (2005). "Sedation in PACU: the role of benzodiazepines".Current Drug Targets.6(7): 745–748.doi:10.2174/138945005774574416.PMID16305452.
  41. ^abBattaglia J (2005). "Pharmacological management of acute agitation".Drugs.65(9): 1207–1222.doi:10.2165/00003495-200565090-00003.PMID15916448.S2CID692414.
  42. ^Zoupanos BN, Bryois C (July 2005). "[Treatment of agitation in the emergency room]" [Treatment of agitation in the emergency room].Revue Médicale Suisse(in French).1(27): 1810–1813.PMID16119296.
  43. ^Huf G, Alexander J, Gandhi P, Allen MH (November 2016)."Haloperidol plus promethazine for psychosis-induced aggression".The Cochrane Database of Systematic Reviews.2016(11): CD005146.doi:10.1002/14651858.CD005146.pub3.PMC6464403.PMID27885664.
  44. ^abGillies D, Sampson S, Beck A, Rathbone J (April 2013)."Benzodiazepines for psychosis-induced aggression or agitation".The Cochrane Database of Systematic Reviews(4): CD003079.doi:10.1002/14651858.CD003079.pub3.hdl:10454/16512.PMID23633309.
  45. ^abBieniek SA, Ownby RL, Penalver A, Dominguez RA (1998). "A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation".Pharmacotherapy.18(1): 57–62.doi:10.1002/j.1875-9114.1998.tb03827.x.PMID9469682.S2CID24505811.
  46. ^Rosebush PI, Mazurek MF (1996). "Catatonia after benzodiazepine withdrawal".Journal of Clinical Psychopharmacology.16(4): 315–319.doi:10.1097/00004714-199608000-00007.PMID8835707.
  47. ^van Dalfsen AN, van den Eede F, van den Bossche B, Sabbe BG (2006). "(title in Dutch)" [Benzodiazepines in the treatment of catatonia].Tijdschrift voor Psychiatrie(in Dutch).48(3): 235–239.PMID16956088.
  48. ^Herrstedt J, Aapro MS, Roila F, Kataja VV (2005)."ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)".Annals of Oncology.16(Suppl 1): i77–i79.doi:10.1093/annonc/mdi805.PMID15888767.
  49. ^Bishop KI, Curran HV (December 1998). "An investigation of the effects of benzodiazepine receptor ligands and of scopolamine on conceptual priming".Psychopharmacology.140(3): 345–353.doi:10.1007/s002130050775.PMID9877014.S2CID21940883.
  50. ^Bishop KI, Curran HV (September 1995). "Psychopharmacological analysis of implicit and explicit memory: a study with lorazepam and the benzodiazepine antagonist flumazenil".Psychopharmacology.121(2): 267–278.doi:10.1007/bf02245638.PMID8545533.S2CID24371644.
  51. ^Kripke DF (February 2016)."Mortality Risk of Hypnotics: Strengths and Limits of Evidence".Drug Safety.39(2): 93–107.doi:10.1007/s40264-015-0362-0.PMID26563222.S2CID7946506.
  52. ^"Ativan side effects".RxList. 2007. Archived fromthe originalon 21 August 2007.Retrieved10 August2007.
  53. ^Sorel L, Mechler L, Harmant J (1981). "Comparative trial of intravenous lorazepam and clonazepam im status epilepticus".Clinical Therapeutics.4(4): 326–336.PMID6120763.
  54. ^Bond A, Lader M (1988). "Differential effects of oxazepam and lorazepam on aggressive responding".Psychopharmacology.95(3): 369–373.doi:10.1007/BF00181949.PMID3137624.S2CID35313827.
  55. ^Pietras CJ, Lieving LM, Cherek DR, Lane SD, Tcheremissine OV, Nouvion S (2005). "Acute effects of lorazepam on laboratory measures of aggressive and escape responses of adult male parolees".Behavioral Pharmacology.16(4): 243–251.doi:10.1097/01.fbp.0000170910.53415.77.PMID15961964.S2CID44387644.
  56. ^Kalachnik JE, Hanzel TE, Sevenich R, Harder SR (2002). "Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation".American Journal on Mental Retardation.107(5): 376–410.doi:10.1352/0895-8017(2002)107<0376:BBSERA>2.0.CO;2.ISSN0895-8017.PMID12186578.
  57. ^Michel L, Lang JP (2003). "(title in French)" [Benzodiazepines and forensic aspects].L'Encéphale(in French).29(6): 479–485.PMID15029082.
  58. ^Mancuso CE, Tanzi MG, Gabay M (2004)."Paradoxical reactions to benzodiazepines: literature review and treatment options".Pharmacotherapy.24(9): 1177–1185.doi:10.1592/phco.24.13.1177.38089.PMID15460178.S2CID38614605.Archivedfrom the original on 13 December 2012.
  59. ^Goldney RD (1977). "Paradoxical reaction to a new minor tranquilizer".Medical Journal of Australia.1(5): 139–140.doi:10.5694/j.1326-5377.1977.tb130567.x.PMID15198.S2CID78865613.
  60. ^Izaute M, Bacon E (2005)."Specific effects of an amnesic drug: effect of lorazepam on study time allocation and on judgment of learning".Neuropsychopharmacology.30(1): 196–204.doi:10.1038/sj.npp.1300564.PMID15483562.S2CID18103662.
  61. ^Scharf MB, Kales A, Bixler EO, Jacoby JA, Schweitzer PK (1982). "Lorazepam-efficacy, side-effects, and rebound phenomena".Clinical Pharmacology and Therapeutics.31(2): 175–179.doi:10.1038/clpt.1982.27.PMID6120058.S2CID464310.
  62. ^Riker RR, Fraser GL (2005). "Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit".Pharmacotherapy.25(5 Pt 2): 8S–18S.doi:10.1592/phco.2005.25.5_Part_2.8S.PMID15899744.S2CID24789150.
  63. ^"FDA expands Boxed Warning to improve safe use of benzodiazepine drug".U.S.Food and Drug Administration(FDA).23 September 2020.Retrieved23 September2020.Public DomainThis article incorporates text from this source, which is in thepublic domain.
  64. ^Guilleminault C (March 1990). "Benzodiazepines, breathing, and sleep".The American Journal of Medicine.88(3A): 25S–28S.doi:10.1016/0002-9343(90)90282-I.PMID1968716.
  65. ^Kanto JH (1982). "Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations".Drugs.23(5): 354–380.doi:10.2165/00003495-198223050-00002.PMID6124415.S2CID27014006.
  66. ^McElhatton PR (1994). "The effects of benzodiazepine use during pregnancy and lactation".Reproductive Toxicology.8(6): 461–475.doi:10.1016/0890-6238(94)90029-9.PMID7881198.
  67. ^abcAuthier N, Balayssac D, Sautereau M, Zangarelli A, County P, Somogyi AA, Vennat B, Llorca PM, Eschalier A (2009). "Benzodiazepine dependence: focus on withdrawal syndrome".Annales Pharmaceutiques Françaises.67(6): 408–413.doi:10.1016/j.pharma.2009.07.001.PMID19900604.
  68. ^Butler JM, Begg EJ (2008). "Free drug metabolic clearance in elderly people".Clinical Pharmacokinetics.47(5): 297–321.doi:10.2165/00003088-200847050-00002.PMID18399712.S2CID8473906.
  69. ^abcOlkkola KT, Ahonen J (2008). "Midazolam and Other Benzodiazepines".Modern Anesthetics.Handbook of Experimental Pharmacology. Vol. 182. pp. 335–360.doi:10.1007/978-3-540-74806-9_16.ISBN978-3-540-72813-9.PMID18175099.
  70. ^Longo LP, Johnson B (2000)."Addiction: Part I. Benzodiazepines – side effects, abuse risk and alternatives".American Family Physician.61(7): 2121–2128.PMID10779253.Archivedfrom the original on 12 May 2008.
  71. ^Ashton HC (April 2001)."Reasons for a diazepam (Valium) taper".benzo.org.uk.Retrieved1 June2007.
  72. ^MacKinnon GL, Parker WA (1982). "Benzodiazepine withdrawal syndrome: a literature review and evaluation".The American Journal of Drug and Alcohol Abuse.9(1): 19–33.doi:10.3109/00952998209002608.PMID6133446.
  73. ^"Ativan Labeling Revision"(PDF).FDA. April 2007.Archived(PDF)from the original on 7 March 2008.Retrieved3 October2007.
  74. ^"Lorazepam: Patient Information Leaflet, UK, 1998".Genus Pharmaceuticals. 21 January 1998.Retrieved14 May2007.
  75. ^"Lorazepam".Patient UK. 25 October 2006.Archivedfrom the original on 27 September 2007.Retrieved14 May2007.
  76. ^Baciewicz AM, Chrisman CR, Finch CK, Self TH (2008). "Update on rifampin and rifabutin drug interactions".American Journal of the Medical Sciences.335(2): 126–136.doi:10.1097/MAJ.0b013e31814a586a.PMID18277121.S2CID42918932.
  77. ^Löscher W, Rogawski MA (December 2012)."How theories evolved concerning the mechanism of action of barbiturates".Epilepsia.53(Suppl 8): 12–25.doi:10.1111/epi.12025.PMID23205959.S2CID4675696.
  78. ^Contribution to the sensible use of benzodiazepines.Strassbourg: Council of Europe, Pompidou Group. 2002.ISBN978-92-871-4751-6.
  79. ^Baselt R (2008).Disposition of Toxic Drugs and Chemicals in Man(8th ed.). Foster City, CA: Biomedical Publications. pp. 860–862.
  80. ^Shaw LM (2001).The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation.Amer. Assoc. for Clinical Chemistry. p. 216.ISBN9781890883539.
  81. ^Ries RK, Miller SC, Fiellin DA (2009).Principles of Addiction Medicine.Lippincott Williams & Wilkins. p. 301.ISBN978-0-7817-7477-2.
  82. ^Kang M, Galuska MA, Ghassemzadeh S (2023)."Benzodiazepine Toxicity".StatPearls.Treasure Island (FL): StatPearls Publishing.PMID29489152.Retrieved13 June2023.
  83. ^Mandrioli R, Mercolini L, Raggi MA (2008)."Benzodiazepine metabolism: an analytical perspective".Current Drug Metabolism.9(8): 827–844.doi:10.2174/138920008786049258.PMID18855614.
  84. ^Pompéia S, Manzano GM, Tufik S, Bueno OF (2005)."What makes lorazepam different from other benzodiazepines?".Journal of Physiology.569(Pt 2): 709, author reply 710.doi:10.1113/jphysiol.2005.569005.PMC1464231.PMID16322061.
  85. ^Chouinard G (2004)."Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound".Journal of Clinical Psychiatry.65(Suppl 5): 7–12.PMID15078112.
  86. ^British Medical AssociationandRoyal Pharmaceutical Society of Great Britain(March 2007).British National Formulary(v53 ed.). London: BMJ and RPS Pub.ISBN978-0-85369-731-2.
  87. ^Nimmo R, Ashton CH (March 2007)."Benzodiazepine Equivalence Table".benzo.org.uk.Retrieved13 May2007.
  88. ^Ashton CH (April 2007)."Benzodiazepine equivalency table".Archivedfrom the original on 28 September 2007.Retrieved23 September2007.
  89. ^abcde"Lorzem Data Sheet".New Zealand Medicines and Medical Devices Safety Authority. 4 June 1999. Archived fromthe originalon 28 September 2007.Retrieved13 May2007.
  90. ^Funderburk FR, Griffiths RR, McLeod DR, Bigelow GE, Mackenzie A, Liebson IA, Nemeth-Coslett R (1988)."Relative abuse liability of lorazepam and diazepam: an evaluation in 'recreational' drug users".Drug and Alcohol Dependence.22(3): 215–222.doi:10.1016/0376-8716(88)90021-X.PMID3234245.
  91. ^Lackner TE (2002)."Strategies for optimizing antiepileptic drug therapy in elderly people".Pharmacotherapy.22(3): 329–364.doi:10.1592/phco.22.5.329.33192.PMID11898891.S2CID45073171.Archivedfrom the original on 15 October 2003.
  92. ^Choudhery V, Townend W (2006)."Lorazepam or diazepam in paediatric status epilepticus".Emergency Medicine Journal.23(6): 472–473.doi:10.1136/emj.2006.037606.PMC2564351.PMID16714516.
  93. ^Henry JC, Holloway R (2006)."Review: lorazepam provides the best control for status epilepticus"(PDF).Evidence Based Medicine.11(2): 54.doi:10.1136/ebm.11.2.54.PMID17213084.S2CID30618719.Archived(PDF)from the original on 12 December 2006.
  94. ^Cock HR, Schapira AH (2002). "A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus".QJM.95(4): 225–231.doi:10.1093/qjmed/95.4.225.PMID11937649.
  95. ^abcGreenblatt DJ, Schillings RT, Kyriakopoulos AA, Shader RI, Sisenwine SF, Knowles JA, Ruelius HW (1976). "Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam".Clinical Pharmacology and Therapeutics.20(3): 329–341.doi:10.1002/cpt1976203329.PMID8232.S2CID76854489.
  96. ^Papini O, Bertucci C, da Cunha SP, dos Santos NA, Lanchote VL (2006). "Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples".Journal of Pharmaceutical and Biomedical Analysis.40(2): 389–396.doi:10.1016/j.jpba.2005.07.033.PMID16243469.
  97. ^Herman RJ, Van Pham JD, Szakacs CB (1989). "Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect".Clinical Pharmacology and Therapeutics.46(1): 18–25.doi:10.1038/clpt.1989.101.PMID2743706.S2CID2092144.
  98. ^Matthew E, Andreason P, Pettigrew K, et al. (1995)."Benzodiazepine receptors mediate regional blood flow changes in the living human brain".Proc. Natl. Acad. Sci. U.S.A.92(7): 2775–2779.Bibcode:1995PNAS...92.2775M.doi:10.1073/pnas.92.7.2775.PMC42301.PMID7708722.
  99. ^Sybirska E, Seibyl JP, Bremner JD, et al. (1993)."[123I]Iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain ".Neuropharmacology.32(7): 671–680.doi:10.1016/0028-3908(93)90080-M.PMID8395663.S2CID43017514.
  100. ^McLean MJ, Macdonald RL (1988). "Benzodiazepines, but not beta-carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture".Journal of Pharmacology and Experimental Therapeutics.244(2): 789–795.PMID2450203.
  101. ^baxter – Lorazepam Injection Data SheetArchived7 May 2007 at theWayback Machine
  102. ^Yaucher NE, Fish JT, Smith HW, Wells JA (2003). "Propylene glycol-associated renal toxicity from lorazepam infusion".Pharmacotherapy.23(9): 1094–1099.doi:10.1592/phco.23.10.1094.32762.PMID14524641.S2CID20496680.
  103. ^American Academy of Hospice and Palliative Medicine,"Five Things Physicians and Patients Should Question",Choosing Wisely:an initiative of theABIM Foundation,American Academy of Hospice and Palliative Medicine,archived fromthe originalon 1 September 2013,retrieved1 August2013,which cites
  104. ^Braestrup C, Squires RF (1978). "Pharmacological characterization of benzodiazepine receptors in the brain".European Journal of Pharmacology.48(3): 263–270.doi:10.1016/0014-2999(78)90085-7.PMID639854.
  105. ^"Benzodiazepine Names".non-benzodiazepines.org.uk. Archived fromthe originalon 8 December 2008.Retrieved29 December2008.
  106. ^Griffiths RR, Johnson MW (2005). "Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds".Journal of Clinical Psychiatry.66(Suppl 9): 31–41.PMID16336040.
  107. ^"Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits".Substance Abuse and Mental Health Services Administration.2006. Archived fromthe originalon 16 March 2014.Retrieved21 February2014.
  108. ^"List of psychotropic substances under international control: Green List 23rd ed"(PDF).Vienna:International Narcotics Control Board.August 2003. p. 7. Archived fromthe original(PDF)on 5 December 2005.
  109. ^"List of Controlled Drugs"(PDF).UK Home Office. January 2006. Archived fromthe original(PDF)on 11 July 2009.
  110. ^Labaton S (13 July 2000)."Generic-Drug Maker Agrees to Settlement In Price-Fi xing Case".The New York Times.Archivedfrom the original on 14 October 2007.Retrieved14 May2007.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lorazepam&oldid=1225712444"